Catalyst Event
Viatris Inc (VTRS) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/23/2026, 12:00:00 AM
Announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Effexor® SR for the treatment of adults with generalized anxiety disorder (GAD), making it the first approved treatment for GAD in Japan.
Korean Translation
일본 후생노동성(MHLW)이 성인 범불안장애(GAD) 치료제로 Effexor® SR을 승인했다고 발표했으며, 이는 일본에서 GAD에 대해 승인된 최초의 치료제가 됨.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
First quarter 2026 earnings release and conference call scheduled.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck is scheduled to release its Q1 2026 financial results before the market opens. Earnings releases typically cause significant price volatility, justifying a Medium importance, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
First quarter 2026 financial results and conference call scheduled for 2026-04-30. Routine earnings announcements typically result in minor price fluctuations (Low importance) scheduled.
4/30/2026, 12:00:00 AM
Medpace Holdings Inc (MEDP) · Earnings Release
First quarter 2026 financial results to be reported after market close on April 22, 2026. Importance is estimated as High as earnings releases typically cause significant price volatility, scheduled.
4/22/2026, 12:00:00 AM